Alexion Appoints Andreas Rummelt to its Board of Directors
CHESHIRE, Conn., Feb 24, 2010 (BUSINESS WIRE) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that
Andreas Rummelt, Ph.D., has been appointed a Director of Alexion,
effective immediately.
About Andreas Rummelt
Dr. Rummelt has more than 25 years of experience in the pharmaceutical
industry, primarily focusing on drug development, technical operations,
quality assurance and global manufacturing strategy. Dr. Rummelt was a
member of the Executive Committee of Novartis from 2006 to 2010, where
he most recently served as Group Head of Quality Assurance and Technical
Operations until 2010.
Dr. Rummelt joined Sandoz Pharma Ltd. in Switzerland in 1985 and held
various positions of increasing responsibility in drug development. In
1994, he was appointed Head of Worldwide Technical Research and
Development, a position he retained following the merger that created
Novartis in 1996. From 1999 to 2004, Dr. Rummelt served as Global Head
of Technical Operations of the Novartis Pharmaceuticals Division. From
2004 to 2008, he was CEO of Sandoz, the generics division of Novartis,
headquartered in Vienna (Austria) and following the acquisition of Hexal
and Eon Labs in 2005 in Holzkirchen (Germany) where he drove the
integration and growth of the businesses.
Dr. Rummelt earned his Ph.D. in Pharmaceutical Sciences from the
University of Erlangen-Nuremberg, Germany.
"We are excited to welcome Dr. Rummelt as a Director," said Max Link,
Ph.D., Chairman of the Board of Directors of Alexion. "His executive
experience and extensive expertise in quality, manufacturing and
technical operations will be of significant value to the company as
Alexion continues its global expansion."
"Andreas' international track record in pharmaceutical production and
supply will be a great asset for Alexion as we accelerate our strategies
for providing Soliris to more patients in more countries around the
world," said Leonard Bell, M.D., Chief Executive Officer of Alexion.
"I am pleased to be joining Alexion's Board at this important moment
when the company has growing resources and a clear vision for meeting
the needs of previously under-served patients worldwide," said Dr.
Rummelt.
About Alexion
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to
develop and deliver life-changing drug therapies for patients with
serious and life-threatening medical conditions. Alexion is engaged in
the discovery, development and commercialization of therapeutic products
aimed at treating patients with a wide array of severe disease states,
including hematologic and kidney diseases, transplant, cancer, and
autoimmune disorders. Soliris(R) (eculizumab), Alexion's first marketed
product, is approved in the U.S., European Union, Australia and Canada
as a treatment for patients with paroxysmal nocturnal hemoglobinuria
(PNH), a rare, debilitating and life-threatening blood disorder. Alexion
is evaluating other potential indications for Soliris as well as other
formulations of eculizumab for additional clinical indications, and is
pursuing development of other antibody product candidates in early
stages of development. This press release and further information about
Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com.
[ALXN-G]
This news release contains forward-looking statements, including
statements related to the Company's global expansion. Forward-looking
statements are subject to factors that may cause Alexion's results and
plans to differ from those expected, including, for example, delays in
establishing commercial infrastructure, the possibility that Alexion
will not be able to expand the use of Soliris into new markets, and a
variety of other risks set forth from time to time in Alexion's filings
with the Securities and Exchange Commission, including but not limited
to the risks discussed in Alexion's Annual Report on Form 10-K
for the year ended December 31, 2009 and in our other filings with the
Securities and Exchange Commission. Alexion does not intend to update
any of these forward-looking statements to reflect events or
circumstances after the date hereof, except when a duty arises under law.
SOURCE: Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Irving Adler, 203-271-8210
Sr. Director, Corporate Communications
or
Media:
Makovsky & Company
Kristie Kuhl, 212-508-9642
or
Investors:
Rx Communications
Felicia Vonella, 917-322-2569
Copyright Business Wire 2010